I agree it should be all over the news but SP now $3.11. We can't assume as to why they haven't expanded on that news but from a laymans perspective if all was good it would have only improved SP by delivering further information. Wonder how executive remuneration packages are set - are they structured on turnover or what is contributed by them once they come on board and will be a bit rich if bonuses are based on the milestone payment due in March given that the contributors of that deal appear to be long gone. Falling SP should not equate to bonuses IMO and also other than the Axiron deal sealed by the previous CEO what other revenue streams are there and forecast to be?. Lots of questions and no responses from head office - yep very concerning IMO. "None" is my current sentiment but am perilously close to "sell". Wonder if these other pharmeceuticals and previous management are providing fierce competition in areas we are not privvy to??. All IMO only so DYOR.
Add to My Watchlist
What is My Watchlist?
